BeOne Medicines (NASDAQ:ONC) Posts Earnings Results, Beats Estimates By $1.30 EPS

BeOne Medicines (NASDAQ:ONC) issued its quarterly earnings data on Thursday. The company reported $3.64 EPS for the quarter, beating the consensus estimate of $2.34 by $1.30, Zacks reports. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.76 billion.

Here are the key takeaways from BeOne Medicines’ conference call:

• Q3 revenue and profitability accelerated: Product revenue rose 33% year over year to about $1.9 billion, while GAAP operating income increased 157% to $419 million. BeOne raised its 2026 revenue outlook to $6.9 billion–$7.0 billion and increased its operating-income guidance.
• BRUKINSA continued to drive growth: Global sales grew 34% to $1.4 billion, with U.S. sales exceeding $1 billion for the first time. Management pointed to strong new-patient starts and real-world evidence, while noting that U.S. sales benefited by about $50 million from order timing.
• Pipeline progress broadened across hematology and solid tumors: BeOne reported encouraging early data for several solid-tumor programs and advanced its B7-H4 ADC into a Phase III trial. The company also said its BTK degrader met the primary endpoint in a Phase II CLL study and that its treatment-naive mantle-cell lymphoma application received FDA priority review.
• Some expected returns may take longer, and investment will remain high: After FDA discussions, BeOne shifted its planned accelerated-approval filing for the BTK degrader in relapsed/refractory CLL to mid-2027, citing a request for additional follow-up. Management expects 2027 operating-expense growth to remain substantial, moderating the pace of margin expansion; it also flagged potential revenue pressure for XGEVA and KYPROLIS from biosimilars and possible China VBP inclusion.

BeOne Medicines Stock Performance

ONC traded up $19.71 during trading on Friday, reaching $406.96. 941,725 shares of the company’s stock were exchanged, compared to its average volume of 364,122. BeOne Medicines has a 1 year low of $253.95 and a 1 year high of $410.71. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.40 and a quick ratio of 3.06. The stock has a market capitalization of $44.68 billion, a P/E ratio of 51.71 and a beta of 0.63. The company’s fifty day simple moving average is $363.49 and its 200-day simple moving average is $326.34.

BeOne Medicines News Roundup

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported Q3 EPS of $3.64, above the $2.34 consensus, and revenue of $1.89 billion, topping estimates of $1.76 billion. The company also raised its 2026 revenue guidance, supporting a stronger outlook. Q3 earnings and guidance
• Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. A faster review could bring a potential label expansion sooner, though approval is not guaranteed. FDA priority review
• Positive Sentiment: Several firms raised price targets while maintaining bullish ratings: RBC to $465, Citizens JMP to $463, Truist to $448, Barclays to $446, and Wells Fargo to $435. The revisions signal continued analyst confidence in BeOne’s prospects. RBC rating information Citizens JMP rating information Truist rating information Barclays rating information Wells Fargo rating information

Insiders Place Their Bets

In other news, insider Titus B. Ball sold 132 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $355.86, for a total value of $46,973.52. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Xiaobin Wu sold 280 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $380.00, for a total transaction of $106,400.00. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 376,373 shares of company stock worth $134,848,154. Company insiders own 6.19% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on ONC shares. Jefferies Financial Group restated a “buy” rating and set a $470.00 target price on shares of BeOne Medicines in a research note on Thursday. Nomura increased their price target on BeOne Medicines from $454.75 to $484.91 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings raised BeOne Medicines from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Morgan Stanley reissued an “overweight” rating and issued a $425.00 price target on shares of BeOne Medicines in a report on Friday, October 16th. Finally, Citigroup restated an “outperform” rating on shares of BeOne Medicines in a research note on Thursday, August 6th. Sixteen research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, BeOne Medicines presently has an average rating of “Moderate Buy” and an average price target of $434.79.

BeOne Medicines Company Profile

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia.

Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.